Andorra Faces Elvanse ADHD Drug Shortage Until Late April

Andorra faces a shortage of lisdexanfetamine, the most commonly used medication for attention deficit hyperactivity disorder (ADHD) and sold under the brand name Elvanse, until the end of April.

The Health Ministry's healthcare resources department announced on Monday that the wholesale supplier has no stock of Elvanse in any of its three available dosages. The sole laboratory producing it will not deliver new batches until late April.

This shortage follows increased prescriptions for lisdexanfetamine after supply issues with methylphenidate-based drugs affected Andorra in 2024 and 2025. Those methylphenidate shortages have now been resolved.

Prescribing doctors should switch patients to available alternatives, including Rubifen, Rubifen Prolong, Medikinet, or Rubicrono in various formulations, the ministry advised in an information note.

Pharmacies must inform patients of the disruption and direct them to consult their physicians for suitable substitutes. During the shortage, these medications can only be dispensed to Andorran residents, with a maximum one-month supply per prescription to preserve limited stocks.

The ministry emphasised careful management of resources, noting that alternative supplies are also under pressure. Patients experiencing difficulties should contact their doctors promptly for adjusted treatments.